Physiologically‐based pharmacokinetic modeling for investigating the effect of simeprevir on concomitant drugs and an endogenous biomarker of OATP1B [PDF]
CPT: Pharmacometrics & Systems Pharmacology, 2023 The orally available anti‐hepatitis C virus (HCV) drug simeprevir exhibits nonlinear pharmacokinetics at the clinical doses due to saturation of cytochrome P450 (CYP) 3A4 metabolism and organic anion transporting peptide (OATP) 1B mediated hepatic uptake.
Shinji Nakayama +4 more
doaj +2 more sources
Molecular Mechanisms of Resistance to Direct-Acting Antiviral (DAA) Drugs for the Treatment of Hepatitis C Virus Infections [PDF]
Diagnostics, 2023 Hepatitis C virus (HCV) is a hepatotropic virus that affects millions of human lives worldwide. Direct-acting antiviral (DAA) regimens are the most effective HCV treatment option.
Mohammad Asrar Izhari
doaj +2 more sources
Elongation factor Tu promotes the onset of periodontitis through mediating bacteria adhesion [PDF]
npj Biofilms and MicrobiomesPeriodontitis, a leading cause of adult tooth loss and linked to various systemic diseases, is promoted by subgingival plaque biofilms, with Streptococci as early colonizers responsible for surface adhesion.
Leyi Xiao +15 more
doaj +2 more sources
Anais da Academia Brasileira de Ciências, 2021 Direct-acting antivirals have revolutionized the treatment of chronic hepatitis C. Sofosbuvir and simeprevir are prescribed worldwide. However, there is a scarcity of information regarding their genotoxicity.
CARINA S. LIBRELOTTO +4 more
doaj +1 more source
Hospital Pharmacy, 2014 Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing ...
Cada, Dennis J +2 more
openaire +3 more sources
Safety and Efficacy of Sofosbuvir Based Regimens in Treating Chronic Hepatitis C Virus in Egyptian Patients: Real World Study: Single Center Experience [PDF]
Afro-Egyptian Journal of Infectious and Endemic Diseases, 2021 Backgroundand study aims:Hepatitis C virus (HCV) is the main leading cause of liver disease in Egypt. A new era of HCV treatment has been started with the evolution of direct acting antiviral agents.
Mohamed Abbasy +6 more
doaj +1 more source
Possibilities of using cepeginterferon alpha-2b in double (cepeginterferon alfa-2b and ribavirin) and triple (simeprevir, cepeginterferon alpha-2b, and ribavirin) antiviral therapy regimens for chronic hepatitis C. A review of clinical trials and experience of everyday clinical practice [PDF]
Терапевтический архив, 2016 Since the incidence of chronic hepatitis C (CHC) increases steadily, the priority of national health care is to provide antiviral therapy (AVT) for the maximum number of patients infected with hepatitis C virus (HCV).
O O Znoyko +5 more
doaj +1 more source
Journal of Education, Health and Sport, 2023 Introduction Cirrhosis is a condition in which the liver becomes fibrotic following damage to the liver and transforms the architecture of the organ into regenerative nodules.
Kamila Abram +9 more
doaj +1 more source
REAL LIFE EGYPTIAN EXPERIENCE OF COMBINATION THERAPY (SIMEPREVIR/SOFOSBUVIR) IN EXPERIENCED NON CIRRHOTIC HCV PATIENTS [PDF]
Al-Azhar Journal of Pharmaceutical Sciences, 2017 Background Egypt has the highest prevalent in presence of chronic HCV infection that may lead to cirrhosis, portal hypertension, hepatocellular failure and hepatocellular carcinoma.
Engy Wahsh
doaj +1 more source
Viruses, 2015 Hepatitis C virus (HCV) infection is one of the leading causes of end-stage liver disease and the main indication for liver transplantation (LT) in most countries.
Bruno Roche +3 more
doaj +1 more source